Reata Pharmaceuticals (RETA) Form 4 REATA PHARMACEUTICALS / R Kent McGaughy Jr ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

McGaughy R Kent Jr

(Last) (First) (Middle)

C/O CPMG, INC.

2000 MCKINNEY AVE, STE 2125

(Street)

DALLAS TX 75201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REATA PHARMACEUTICALS INC [ RETA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/10/2018

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock	12/10/2018		P		26,174	A	$57.9329(6)	2,938,697	I	See Footnote(1)(5)
Class A common stock	12/10/2018		P		1,078	A	$58.6218(7)	2,939,775	I	See Footnote(1)(5)
Class A common stock	12/10/2018		P		29,347	A	$59.5303(8)	2,969,122	I	See Footnote(1)(5)
Class A common stock	12/11/2018		P		52,809	A	$60.0719(9)	3,021,931	I	See Footnote(1)(5)
Class A common stock	12/12/2018		P		1,418	A	$59.8952(10)	3,023,349	I	See Footnote(1)(5)
Class A common stock								4,591	I	By Lagos Trust(2)(5)
Class A common stock								280	I	By Traweek Children's Trust(3)(5)
Class A common stock								2,739	I	See footnote(4)(5)
Class A common stock								25,004	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of Class A common stock are held in various funds for which CPMG, Inc. serves as investment manager. The Reporting Person is a co-director and co-shareholder of CPMG, Inc.

2. The Reporting Person is trustee of Lagos Trust.

3. The Reporting Person is trustee of Traweek Children's Trust.

4. These shares of Class A common stock are held in escrow for a charitable donee by American Stock Transfer & Trust Company, LLC.

5. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

6. This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range. The actual prices for these transactions range from $57.235 to $58.23, inclusive. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price within the ranges set forth in footnotes (6) through (10) to this Form 4.

7. This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range. The actual prices for these transactions range from $58.235 to $59.17, inclusive.

8. This price reflects the weighted average purchase price for open-market purchases on December 10, 2018, within a $1.00 range. The actual prices for these transactions range from $59.24 to $59.80, inclusive.

9. This price reflects the weighted average purchase price for open-market purchases on December 11, 2018, within a $1.00 range. The actual prices for these transactions range from $59.52 to $60.145, inclusive.

10. This price reflects the weighted average purchase price for open-market purchases on December 12, 2018, within a $1.00 range. The actual prices for these transactions range from $59.84 to $59.98, inclusive.

	/s/ R. Kent McGaughy, Jr.	12/12/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.